Mirae Asset's Tiger S&P 500 ETF becomes Korea's largest by net assets
According to data from the Korea Exchange, the S&P 500 ETF's net assets stood at 8.54 trillion won ($6.21 billion) as of Thursday. Buoyed by strong interest from retail investors, the fund has ranked first in net purchases by individuals in both 2024 and the first half of 2025, earning it the nickname 'Korea's national ETF.'
Since the launch of Korea's ETF market in 2002, domestic equity and bond ETFs have dominated the rankings. The rise of the Tiger S&P 500 ETF signals a shift from this, showing growing demand for US stock exposure, as ETFs are considered an easier alternative to direct stock purchases.
Mirae Asset plans to continue enhancing the fund's competitiveness as a core vehicle for long-term US equity investment. The fund's total expense ratio stands at just 0.0768 percent, with an all-in cost of 0.1182 percent, which is the lowest among S&P 500 ETFs listed in Korea.
To mark the milestone, Mirae Asset is holding a promotional 'Tiger US S&P 500 ETF Net Asset No.1 Celebration Event' from July 11 to August 8, offering prizes to selected participants.
Additionally, as of end-June, individual investors held 27.1 trillion won ($19.7 billion) in Tiger ETFs, accounting for 43 percent of all personal ETF holdings in Korea.
'This milestone reflects our long-standing efforts to build a US index investment culture, starting with Korea's first Nasdaq ETF in 2010 and its first S&P 500 ETF in 2020,' said Kim Nam-ki, head of the ETF division at Mirae Asset. 'Despite global market uncertainties, we encourage investors to stay focused on the long-term growth potential of capital markets.'
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Korea Herald
2 days ago
- Korea Herald
OSR Holdings Provides Strategic Update on Woori IO Term Sheet and Share Exchange Structure
BELLEVUE, Wash. and SEOUL, South Korea, July 31, 2025 /PRNewswire/ -- OSR Holdings, Inc. (NASDAQ: OSRH), a global healthcare company advancing biomedical and wellness innovation, today issued a strategic update regarding its recently announced Term Sheet with Woori IO Co., Ltd. ("WORIO"), a South Korean medical device company pioneering noninvasive glucose monitoring technology. The transaction, once completed, will result in WORIO becoming a wholly owned subsidiary of OSR Holdings Co., Ltd. ("OSRK"), a Korean affiliate of OSRH. As previously disclosed, WORIO shareholders will receive newly issued OSRK shares, along with a conditional right to exchange those shares for OSRH common stock if OSRH's share price reaches $10.00 or more within three years from the signing of the Term Sheet. WORIO Shareholders Align with OSRH Upside The company emphasizes that the $10 OSRH share condition is intended as a performance-aligned incentive, reflecting WORIO shareholders' long-term confidence in OSRH's growth potential. Rather than requesting immediate liquidity, the Sellers — WORIO's shareholders — have agreed to convert their OSRK shares into OSRH shares only upon OSRH reaching $10.00 per share, representing a nearly 10x premium over recent trading levels. "This is not a dilution event, but a strong vote of confidence," said Peter Hwang, CEO of OSR Holdings. "WORIO's shareholders are betting on our ability to realize transformative value and are choosing to stay aligned with OSRH shareholders for the long term. That alignment is a positive signal for the market." If OSRH's share price does not meet the $10.00 threshold within three years, the conversion will not occur, and WORIO shareholders will remain equity holders in the privately held OSRK entity. The companies have agreed to renegotiate in good faith at that time, if necessary. Noninvasive Glucose Monitoring: A Transformational Market The strategic rationale behind the transaction lies in the tremendous unmet need and market potential for noninvasive glucose monitoring. Today's global CGM (continuous glucose monitoring) market — dominated by companies like Dexcom and Abbott — still relies on minimally invasive sensors that require skin penetration or consumables. WORIO's technology leverages near-infrared spectroscopy (NIRS) to deliver accurate, needle-free glucose measurement. This makes it well suited for integration into wearable devices such as smartwatches. The company has already completed a proof-of-concept study at Korea University Hospital and is now preparing for a larger confirmatory study for regulatory approval in Korea. "WORIO gives OSRH a unique opportunity to enter this global market before the technology reaches commercial maturity," added Mr. Hwang. "This transaction positions our shareholders to benefit from a future that could redefine diabetes management — without the burden of invasive devices." Industry Landscape and Strategic Positioning According to industry reports, the global blood glucose monitoring device market is projected to exceed $40 billion by 2030, with strong tailwinds from rising diabetes prevalence and increasing demand for painless, real-time monitoring. "Imagine the difference this technology could make for individuals who face the daily burden of monitoring blood glucose and navigating the complexity of current invasive devices," said Dr. Constance Höfer, CSO of OSRH. "Beyond the clear advantages for patients and their caregivers, this new non-invasive device could also generate valuable novel datasets—for example, in patients at early stages of metabolic syndrome, studies on cancer relapse and the benefits of exercise, or research exploring the effects of pre- and probiotics on human health and the optimization of elite athletic performance." To date, no company worldwide has received regulatory approval for truly noninvasive glucose monitoring. Media coverage of startups like Afon Technology in Europe underscore the growing interest and momentum in this field, yet few players have established both a working prototype and a regulatory engagement plan. WORIO represents one of the rare companies globally to meet both criteria — and OSRH is positioned as an early acquirer ahead of full commercialization. In Q1 2025, WORIO was selected to participate in Samsung Electronics' innovative startup program, C-Lab Outside. Next Steps Under the 6-month exclusivity period set forth in the Term Sheet, OSRH will continue confirmatory legal, financial, and technical due diligence, with a target to execute definitive agreements within that window. The company looks forward to further engaging with investors as this transaction develops. About OSR Holdings, Inc. OSR Holdings, Inc. (NASDAQ: OSRH) is a global healthcare holding company dedicated to advancing biomedical innovation approaches to health and wellness. Through its subsidiaries, OSRH is engaged in immuno-oncology, regenerative biologics, and medical device technologies. Its vision is to build a portfolio of breakthrough healthcare solutions to improve global health outcomes. Learn more at About Woori IO Co., Ltd. Woori IO is a South Korea-based medical device company developing noninvasive biosensing technologies for glucose monitoring and beyond. Its proprietary NIRS-based system enables accurate, pain-free glucose tracking and is designed for integration into wearables. Visit for more information. Forward-Looking Statements This press release contains forward-looking statements, including expectations regarding the proposed acquisition of Woori IO, future stock performance, regulatory approvals, and market potential. These statements are based on current assumptions and involve risks and uncertainties that could cause actual results to differ materially. OSR Holdings undertakes no obligation to update these statements except as required by law.
Korea Herald
3 days ago
- Korea Herald
Seoul shares open flat amid intense US tariff talks
South Korean stocks opened nearly unchanged Wednesday after reaching a four-year high the previous session amid uncertainties over high-stakes tariff talks with the United States. The benchmark Korea Composite Stock Price Index added 1.88 points, or 0.06 percent, to 3,232.45 in the first 15 minutes of trading. South Korea continued intensive negotiations with the US to reach a deal on President Donald Trump's administration's sweeping tariff scheme before the Aug. 1 deadline. In the latest round of meetings, Finance Minister Koo Yun-cheol, Industry Minister Kim Jung-kwan and Trade Minister Yeo Han-koo held two-hour talks with US Commerce Secretary Howard Lutnick in Washington on Tuesday, according to Koo's office. Overnight, US stocks lost ground awaiting the Federal Reserve's monetary decision Wednesday. The Dow Jones Industrial Average lost 0.46 percent, and the tech-heavy Nasdaq composite shed 0.38 percent. The S&P 500 index fell 0.3 percent. Top-cap shares traded mixed. Market bellwether Samsung Electronics surged 1.84 percent, and chip giant SK hynix edged up 0.19 percent. Leading battery maker LG Energy Solution shed 0.64 percent, and major bio company Samsung Biologics fell 0.46 percent. Defense giant Hanwha Aerospace sank 2.1 percent, while leading financial firm KB Financial inched up 0.09 percent. Nuclear power plant manufacturer Doosan Enerbility tumbled 2 percent. Top automaker Hyundai Motor opened unchanged, while its sister affiliate Kia increased 0.47 percent. Top online portal operator Naver climbed 0.86 percent, while leading steelmaker POSCO dipped 1.26 percent. The local currency was trading at 1,388.4 won against the greenback at 9:15 a.m., up 2.6 won from the previous session. (Yonhap)
Korea Herald
3 days ago
- Korea Herald
Trump gets tariffs; Americans get price hikes
US President Donald Trump is getting his tariffs. Companies are making it clear how they intend to deal with it — passing them on to American consumers. Throughout the spring, big retailers and consumer product makers warned that levies on imported goods would squeeze their operations, forcing them to choose between lower earnings and passing on higher costs to customers. In the case of Procter & Gamble and others, it is both of those things. On Tuesday, the packaging giant, which makes household basics spanning from Bounty paper towel to Tide detergent, issued a sour outlook for 2025 and sent a message to big retailers like Walmart that it would have to raise prices on some US goods from next week. This challenge facing companies in coming quarters will likely feed through to everyday consumers. P&G said it would raise prices on about a quarter of its products in the US to help offset the cost of new tariffs. Price hikes are in the mid-single digits across categories, a spokesperson for the company said. While US stock indexes have soared to record highs this year, built on massive investment in technology shares, many consumer bellwethers have struggled. Since Trump's April 2 "Liberation Day" tariff announcements, P&G shares have declined 19 percent; Nestle is down 20 percent; Kimberly-Clark has lost 11 percent, and PepsiCo is off nearly 7 percent, while the benchmark S&P 500 stock index has gained more than 13 percent. Consumer goods, food and drink companies have struggled with lackluster sales since the pandemic, as shoppers have balked at increasingly expensive name-brand packaged food. Nestle said last week that consumers in North America remained wary of paying more at the cash register. More price hikes will deepen investor worries about how big brands are navigating the combined challenge of thrifty consumers and hefty costs created by Trump's trade war. "You're going to see companies like Walmart, Amazon, and Best Buy forced to pass price increases to consumers," said Bill George, former chairman and CEO of Medtronic and executive education fellow at Harvard Business School. "Main Street has yet to see the fallout from increased tariffs - and they're going to go higher." Between July 16 and 25, companies in the Reuters global tariff tracker said they expected to lose a combined $7.1 billion to $8.3 billion for the full year. GM, Ford and other carmakers have absorbed the cost of tariffs — totaling billions of dollars — so far. Many companies shipped more goods and raw materials into the US before tariffs hit. Economists and analysts reckon that hoarding has helped some delay hiking prices until later in the year and explains why tariffs have not yet shown up in US inflation data. Andrew Wilson, International Chamber of Commerce deputy secretary general, estimates inflation will be felt once companies have run down inventory, but that might not be until the fourth quarter or first quarter of next year. Others like Ray Ban-maker EssilorLuxottica have already hiked prices. Swiss watch and jewelry maker Swatch increased prices by about 5 percent after Trump announced tariffs in April with "zero impact" on sales, CEO Nick Hayek told Reuters recently. High-end brands like Tissot watches are less price sensitive to increases. Customers wanting to splash out on an expensive watch might also buy abroad when travelling where taxes are lower, he said.
